Nabriva Therapeutics plc — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c6a8c0fc-408c-483c-8d41-6a3ae0e6c294/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-57.2M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-006062 |
| FY 2021 | $-49.5M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-004615 |
| FY 2020 | $-69.5M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002824 |
| FY 2019 | $-82.8M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-002547 |
| FY 2018 | $-114.8M | 2018-01-01 – 2018-12-31 | evidence 0001047469-19-001138 |
| FY 2017 | $-74.4M | 2017-01-01 – 2017-12-31 | evidence 0001047469-18-001768 |
| FY 2016 | $-54.9M | 2016-01-01 – 2016-12-31 | evidence 0001104659-17-019162 |
| FY 2015 | $-47.0M | 2015-01-01 – 2015-12-31 | evidence 0001104659-17-019162 |
| FY 2014 | $-14.2M | 2014-01-01 – 2014-12-31 | evidence 0001104659-17-019162 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Nabriva Therapeutics plc — all facts · Revenue · Operating Income